HCSCI Secures Tens of Millions in Series A+ Funding to Advance Automated Molecular Diagnostics
VCBeat learned on March 24 that Chengdu Hanchenguangyi Technology Co., Ltd. (hereinafter referred to as “Hanchenguangyi”), a company specializing in automated molecular diagnostic equipment, announced that it had completed tens of millions of yuan in Series A+ financing earlier this year. The investors included Northern Light Venture Capital, Boyuan Capital, Fosun Group’s Star Future Capital, and Yunzhi Capital.The funds raised will accelerate Chengdu Hanchenguangyi Technology Co., Ltd.’s R&D, market expansion, and team building for automated molecular diagnostic equipment, hastening its emergence as a leading enterprise in China’s automated molecular diagnostics sector.
Chengdu Hanchenguangyi Technology Co., Ltd. is a high-tech enterprise integrating equipment R&D, production, and marketing. It focuses on the independent development and promotion of various automated molecular detection instruments to meet the growing application needs of customers in China and worldwide in fields such as clinical molecular diagnostics, health genetic testing, and agricultural molecular breeding. The company has previously completed multiple rounds of financing.
Chengdu Hanchenguangyi Technology Co., Ltd. Financing Status
According to Dr. Zhang Han, CEO of Chengdu Hanchenguangyi Technology Co., Ltd., high automation, integration, and high throughput represent one of the key development trends in equipment technology within the molecular diagnostics industry. Leveraging its R&D strengths, Hanchenguangyi will seize opportunities to deploy innovative technologies in the upstream equipment segment of China’s molecular diagnostics market, strengthen multi-party collaborative promotion, and accelerate the autonomous, integrated, and automated innovation-driven development of China’s molecular diagnostics industry.
Molecular testing is widely used in clinical disease diagnosis, precision medicine, health management, modern agriculture, and other fields, offering advantages such as high specificity, high sensitivity, and a broad detection range. Currently, China’s molecular testing sector is in a phase of rapid growth, with significant market potential. Dr. Zhang Han stated:“Although molecular testing offers significant advantages, its complex procedures and stringent requirements for laboratory personnel and facilities have constrained its development.”Furthermore, the sample preprocessing workflow for molecular testing is complex, and manual operation of molecular diagnostic instruments is cumbersome. Consequently, high-throughput, fully automated molecular diagnostic platforms have emerged.
Currently, companies such as Roche and Qiagen have already launched high-throughput, fully automated molecular diagnostic devices abroad. In contrast, domestic enterprises in China started later in this field, and very few Chinese manufacturers possess independent intellectual property rights for such equipment. Dr. Zhang Han stated, “The technical barriers to developing fully automated molecular testing instruments are extremely high. Challenges such as ensuring the stability of these devices, preventing aerosol contamination, and achieving precise temperature and fluid control have all hindered the development of automated molecular testing equipment in China.”
GeneMatrix, under Chengdu Hanchenguangyi Technology Co., Ltd., is one of the few high-throughput, automated molecular testing systems in China with independent intellectual property rights, achieving import substitution.It has been widely used in China’s modern agriculture, scientific research, health management, and other fields, earning extensive customer recognition. In addition, Chengdu Hanchenguangyi Technology Co., Ltd. is steadily developing multiple high-throughput fully automated molecular diagnostic systems.
Deng Feng, founder of Northern Light Venture Capital, stated that with the development of upstream sequencing technologies, more clinical-grade molecular diagnostic applications will emerge in the future.We anticipate that high-throughput, fully automated molecular diagnostic equipment can address current challenges such as operational complexity, slow processing speeds, and susceptibility to contamination, thereby facilitating the rapid deployment of these new applications.Hanchen Guangyi possesses a global perspective and extensive experience in the development of high-throughput molecular diagnostic equipment. With strong learning capabilities, the team swiftly aligned its strategic layout and product line planning with domestic needs upon returning to China, establishing long-term collaborative relationships with industry peers. Northern Light Venture Capital has invested in Hanchen Guangyi for two consecutive rounds, confident that the team can address longstanding pain points in the industry, accelerate the launch of high-quality products, and benefit more patients.
Tao Feng, Founding Partner of Boyuan Capital, stated: “Compared with biochemical and immunological testing, molecular diagnostics involves more complex operations and imposes higher requirements on laboratory personnel and facilities. This is one of the factors constraining the widespread adoption of molecular diagnostic projects across hospitals of different tiers in China.” As an investor who has continuously increased its investment in Hanchenguangyi since the Series A round,We believe that Chengdu Hanchenguangyi’s fully automated molecular diagnostics solution is poised to break the long-standing monopoly held by imported brands in this field, providing hospitals and patients with more efficient diagnostic services at more reasonable prices, thereby enabling hospitals and physicians to benefit a greater number of patients.